NCT03750422 is a NA clinical trial of Picoway in Striae; Albicantes, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

Who is sponsoring NCT03750422?

NCT03750422 is sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

What drugs are being tested in NCT03750422?

Interventions in NCT03750422: Picoway, Stratacel, Aquasonic.

What condition does NCT03750422 study?

NCT03750422 studies Striae; Albicantes.

Is NCT03750422 still recruiting?

NCT03750422 is currently status unknown. Last updated 10 May 2019.

Last reviewed 2019-05-10 · How we verify

NCT03750422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stretch Marks on Abdomen

Status unknown NA Last updated 10 May 2019

What this trial tests

NA trial testing Picoway in Striae; Albicantes in 20 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
30 November 2019

31 December 2019

Quick facts

Lead sponsor	Goldman, Butterwick, Fitzpatrick and Groff
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	1 July 2018
Primary completion	30 November 2019
Estimated completion	31 December 2019
Sites	1 location across United States

Drugs / interventions tested

Picoway
Stratacel
Aquasonic

Conditions studied

Striae; Albicantes — all drugs for Striae; Albicantes →

Sponsor

Goldman, Butterwick, Fitzpatrick and Groff — full company profile →

Who can join

18 and older, any sex, with Striae; Albicantes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine the effect of Stratacel® wound dressing on cosmetic outcomes following 1064/532nm picosecond laser (Picoway®, Syneron Candela Corp, Wayland, MA, USA) treatment of abdominal striae alba. Secondary objectives include examining the effect of Stratacel® wound dressing on post-laser healing and symptomatology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Goldman, Butterwick, Fitzpatrick and Groff trials

Trials by the same sponsor.

NCT07462533 — Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing · Phase 2 · not yet recruiting
NCT07421544 — Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines · Phase 4 · not yet recruiting
NCT07342413 — Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the · Phase 4 · not yet recruiting
NCT07221461 — Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists · Phase 2 · not yet recruiting
NCT07217743 — Assess Impact of Poly-L-lactic Acid on GLP1 Subjects · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03750422 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Goldman, Butterwick, Fitzpatrick and Groff
Last refreshed: 10 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03750422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing